Navigation Links
Nektar Announces Retirement of Irwin Lerner from Board of Directors
Date:1/29/2009

SAN CARLOS, Calif., Jan. 29 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that Irwin Lerner has retired from its Board of Directors effective January 23, 2009. Mr. Lerner, former Chairman of Hoffmann-La Roche Inc., has been a member of the Nektar Board of Directors since 1999. He is retiring due to personal reasons.

The Board of Directors and the Company wish to acknowledge the contributions that Mr. Lerner has made by providing the benefit of his extensive industry experience to Nektar over a near ten-year period.

"It is a privilege to have worked with Irwin as a colleague and advisor," said Howard W. Robin, President and CEO of Nektar and member of the Board of Directors. "On behalf of the entire Board and the Company, we extend our deepest appreciation to Irwin for his many years of service to Nektar."

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies. Nektar is also developing a robust pipeline of its own high-value therapeutics that addresses unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules. More information on Nektar is available at http://www.nektar.com

     Jennifer Ruddock, 650-631-4954
     jruddock@nektar.com

     Susan A. Noonan, 212-966-3650
     The SAN Group
     Susan@sanoonan.com

'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
2. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
3. Nektar Therapeutics to Webcast R&D Day on November 12th
4. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
5. Nektar Therapeutics President and CEO Howard W. Robin to Present at Natixis Bleichroeder Second Annual Hidden Gems Conference in New York City
6. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City
7. Nektar to Announce Financial Results for the Second Quarter of 2008 on Wednesday, August 6, 2008, After Close of U.S.-Based Financial Markets
8. Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit
9. Nektars PEGylation Technology Enables Peptide Mimetic, Highlighted by Data Presented at 45th ERA-EDTA Congress
10. Nektar Receives Patent Covering Pulmonary Targeted Antibiotics
11. Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/8nqqdw/global_breast ) has announced ... Monoclonal Antibodies Market Outlook 2020" report to ... dominate the breast cancer monoclonal antibody segment because ... has been able to dominate this segment for ... cells become recalcitrant and relapsed condition could not ...
(Date:5/27/2015)... May 27, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) ... 31, 2015. Aviv Boim , ... pre-clinical work to generate functional specific antibodies, targeting identified ... we are encouraged by the development progress. We are ... antibodies which modulate immune checkpoints gain clinical acceptance for ...
(Date:5/27/2015)... Md. , May 27, 2015  Northwest Biotherapeutics, ... company developing DCVax® personalized immune therapies for cancer, announced ... Technical Officer of the Company, will be making an ... Meeting in Chicago on Saturday, ... at the Industry Expert Theater in McCormick Place. ...
(Date:5/27/2015)... May 27, 2015  RXi Pharmaceuticals Corporation (NASDAQ: ... discovering and developing innovative therapies primarily in the ... on the status of the Company,s Series A ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ... 21 shares of Series A Preferred Stock and ...
Breaking Biology Technology:Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 2Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 3Tikcro Technologies Reports First Quarter 2015 Results 2Tikcro Technologies Reports First Quarter 2015 Results 3NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 2NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 3RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3
... Oncology Adjuvant Trial 9735 at 2007 San, ... Improved Overall Survival Versus ... Results presented at the,30th annual San Antonio ... early stage breast cancer who have had surgery, ...
... FDA-defined Valvulopathy Permitted to Enroll in 2nd and ... Screening Requirement Eliminated, SAN DIEGO, Dec. 13 ... announced the initiation of patient screening in,the second ... efficacy and,safety of its lead drug candidate, lorcaserin ...
... SAN DIEGO, Dec. 13 BioMed Realty Trust, Inc.,(NYSE: ... I. Gilchrist to its,board of directors, increasing the board ... in the real estate industry, with a breadth of,ability ... large-scale commercial real estate projects. We believe that,Rick,s contributions ...
Cached Biology Technology:Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 2Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 3Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 4Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 5Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 2Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 3Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 4Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 5Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 6BioMed Realty Trust Appoints Executive Officer of the Irvine Company to Its Board 2BioMed Realty Trust Appoints Executive Officer of the Irvine Company to Its Board 3
(Date:5/22/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... its promotional pricing and making the Wocket generally available for ... , Head of Marketing said, "We,ve extended the opportunity to ... of May. To get your wocket at this special price, ... store on June 1, you,ll receive a unique code that ...
(Date:5/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... LLC, a company engaged in biometric identification is an ... portion of the recently awarded TIES (Technical Information Engineering ... Army. 3D-ID LLC has a suite of ... and security agencies. Gino Pereira , ...
(Date:5/14/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) has ... in Smart Mobile Devices " report to their ... a watershed year for fingerprint sensors in smartphones and ... gave fingerprint sensors a raison d,etre in the mobile ... a must-have feature in flagship smartphones. The ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2
... is challenging because drugs often affect children differently than ... the ability of doctors and scientists to predict drug ... gap, the National Institutes of Health announced today 18 ... likelihood of success of future trials of treatments for ...
... good for their diets, but half still continue to shake ... Alberta researchers. In a survey of 890 people measuring ... researchers Anna Farmer and Diana Mager discovered that the majority ... most are aware that too much sodium can lead to ...
... 2009) Tufts University researchers have identified a gene-diet interaction ... their findings in three independent studies. Men and women ... (BMI) scores and a higher incidence of obesity, but ... fat. These associations were seen in the apolipoprotein A-II ...
Cached Biology News:NIH awards $8.5 million for research on pharmaceuticals for children 2NIH awards $8.5 million for research on pharmaceuticals for children 3Canadians finding it tough to shake the salt habit 2Nutrigenomics researchers replicate gene interaction with saturated fat 2Nutrigenomics researchers replicate gene interaction with saturated fat 3
... The Staccato Application Series are ... systems designed to provide fast and ... Utilizing proven and robust "automation-friendly" building ... solutions that cost less than conventional ...
... Guava has made microcapillary flow cytometry accessible ... experts alike will appreciate the latest addition ... Pluseasy to use, surprising affordable, and very ... system includes such features as absolute cell ...
... Rotator, variable speed, timer, SB3, Fully adjustable ... of tube holders to hold a number ... SB3 is ideal for aerating cultures, keeping ... mixing applications., The rotator can be used ...
... Accuri's C6 Flow Cytometer System is a full ... system including: the C6 Flow Cytometer, CFlow Software, ... C6 Flow Cytometer System provides all the capabilities ... fraction of the price. The C6 Flow Cytometer ...
Biology Products: